The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group.
4/5 보강
TL;DR
The treatment of benign prostatic hyperplasia with 5 mg of finasteride per day results in a significant decrease in symptoms of obstruction, an increase in urinary flow, and a decrease in prostatic volume, but at a slightly increased risk of sexual dysfunction.
📑 코퍼스 인용 관계
· 인용됨 21
📑 인용한 논문 (6) ▾
- SRD5A2 and emerging therapies in androgen-driven disorders. Nature reviews. Urology · 2026
- Prostate zonal impact of 5α-reductase inhibitors on multiparametric MRI characteristics an… BJU international · 2026
- Temperature-dependent phase transition microemulsions for enhanced transdermal delivery of… Scientific reports · 2025
- Comment on Current Investigations into the Postfinasteride Syndrome. International journal of trichology · 2024
- Food Administration and Not Genetic Variants Causes Pharmacokinetic Variability of Tadalaf… Journal of personalized medicine · 2023
- Post-Finasteride Syndrome: An Induced Delusional Disorder with the Potential of a Mass Psy… Skin appendage disorders · 2019
연도별 인용 (2012–2026) · 합계 274
OpenAlex 토픽 ·
Urinary Bladder and Prostate Research
Urinary Bladder and Prostate Research
Sexual function and dysfunction studies
Abstract 🌐 Abstract
[BACKGROUND] Benign prostatic hyperplasia is a progressive, androgen-dependent disease resulting in enlargement of the prostate gland and urinary obstruction. Preventing the conversion of testosterone to its tissue-active form, dihydrotestosterone, by inhibiting the enzyme 5 alpha-reductase could decrease the action of androgens in their target tissues; in the prostate the result might be a decrease in prostatic hyperplasia and therefore in symptoms of urinary obstruction.
[METHODS] In a double-blind study, we evaluated the effect of two doses of finasteride (1 mg and 5 mg) and placebo, each given once daily for 12 months, in 895 men with prostatic hyperplasia. Urinary symptoms, urinary flow, prostatic volume, and serum concentrations of dihydrotestosterone and prostate-specific antigen were determined periodically during the treatment period.
[RESULTS] As compared with the men in the placebo group, the men treated with 5 mg of finasteride per day had a significant decrease in total urinary-symptom scores (P less than 0.001), an increase of 1.6 ml per second (22 percent, P less than 0.001) in the maximal urinary-flow rate, and a 19 percent decrease in prostatic volume (P less than 0.001). The men treated with 1 mg of finasteride per day did not have a significant decrease in total urinary-symptom scores, but had an increase of 1.4 ml per second (23 percent) in the maximal urinary-flow rate, and an 18 percent decrease in prostatic volume. The men given placebo had no changes in total urinary-symptom scores, an increase of 0.2 ml per second (8 percent) in the maximal urinary-flow rate, and a 3 percent decrease in prostatic volume. The frequency of adverse effects in the three groups was similar, except for a higher incidence of decreased libido, impotence, and ejaculatory disorders in the finasteride-treated groups.
[CONCLUSIONS] The treatment of benign prostatic hyperplasia with 5 mg of finasteride per day results in a significant decrease in symptoms of obstruction, an increase in urinary flow, and a decrease in prostatic volume, but at a slightly increased risk of sexual dysfunction.
[METHODS] In a double-blind study, we evaluated the effect of two doses of finasteride (1 mg and 5 mg) and placebo, each given once daily for 12 months, in 895 men with prostatic hyperplasia. Urinary symptoms, urinary flow, prostatic volume, and serum concentrations of dihydrotestosterone and prostate-specific antigen were determined periodically during the treatment period.
[RESULTS] As compared with the men in the placebo group, the men treated with 5 mg of finasteride per day had a significant decrease in total urinary-symptom scores (P less than 0.001), an increase of 1.6 ml per second (22 percent, P less than 0.001) in the maximal urinary-flow rate, and a 19 percent decrease in prostatic volume (P less than 0.001). The men treated with 1 mg of finasteride per day did not have a significant decrease in total urinary-symptom scores, but had an increase of 1.4 ml per second (23 percent) in the maximal urinary-flow rate, and an 18 percent decrease in prostatic volume. The men given placebo had no changes in total urinary-symptom scores, an increase of 0.2 ml per second (8 percent) in the maximal urinary-flow rate, and a 3 percent decrease in prostatic volume. The frequency of adverse effects in the three groups was similar, except for a higher incidence of decreased libido, impotence, and ejaculatory disorders in the finasteride-treated groups.
[CONCLUSIONS] The treatment of benign prostatic hyperplasia with 5 mg of finasteride per day results in a significant decrease in symptoms of obstruction, an increase in urinary flow, and a decrease in prostatic volume, but at a slightly increased risk of sexual dysfunction.
The treatment of benign prostatic hyperplasia with 5 mg of finasteride per day results in a significant decrease in symptoms of obstruction, an increase in urinary flow, and a decrease in prostatic vo
APA 7
Gormley, G. J., Stoner, E., Bruskewitz, R. C., Imperato-McGinley, J., Walsh, P. C., McConnell, J. D., Andriole, G. L., Geller, J., Bracken, B. R., & Tenover, J. S. (1992). The effect of finasteride in men with benign prostatic hyperplasia. The finasteride study group.. The New England journal of medicine, 327(17), 1185-91. https://doi.org/10.1056/NEJM199210223271701
Vancouver
Gormley GJ, Stoner E, Bruskewitz RC, Imperato-McGinley J, Walsh PC, McConnell JD, et al. The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group. New Engl. jour. medi.. 1992;327(17):1185-91. doi:10.1056/NEJM199210223271701
AMA 11
Gormley GJ, Stoner E, Bruskewitz RC, Imperato-McGinley J, Walsh PC, McConnell JD, et al. The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group. New Engl. jour. medi.. 1992;327(17):1185-91. doi:10.1056/NEJM199210223271701
Chicago
Gormley, G. J., Stoner, E., Bruskewitz, R. C., Imperato-McGinley, J., Walsh, P. C., McConnell, J. D., Andriole, G. L., Geller, J., Bracken, B. R., and Tenover, J. S.. 1992. "The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group." The New England journal of medicine 327 (17): 1185-91. https://doi.org/10.1056/NEJM199210223271701
MLA 9
Gormley, G. J., et al. "The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group." The New England journal of medicine, vol. 327, no. 17, 1992, pp. 1185-91. doi:10.1056/NEJM199210223271701.
PMID
1383816 ↗
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
인용 관계
그래프 OA 노드: 8/8 (100%)
· 참조 0편 · 후속 8편
이 논문을 인용한 후속 연구 20
- Adverse Effects and Safety of 5-alpha Reductase Inhibitors (Finasteride, Dutasteride): A Systematic …
- Characteristics of Men Who Report Persistent Sexual Symptoms After Finasteride Use for Hair Loss.
- Development of finasteride polymer microspheres for systemic application in androgenic alopecia.
- The Impact of 5α-Reductase Inhibitor Use for Male Pattern Hair Loss on Men's Health.
- Persistent sexual dysfunction and depression in finasteride users for male pattern hair loss: a seri…
- Post-Finasteride Syndrome: An Induced Delusional Disorder with the Potential of a Mass Psychogenic I…
- A Comment on the Post-Finasteride Syndrome.
- Finasteride concentrations and prostate cancer risk: results from the Prostate Cancer Prevention Tri…
- Connexin 43 expression in the testes during postnatal development of finasteride-treated male rat of…
- Anti-proliferative activities of finasteride in benign prostate epithelial cells require stromal fib…
- Evidence for the efficacy and safety of tadalafil and finasteride in combination for the treatment o…
- Finasteride treatment alters tissue specific androgen receptor expression in prostate tissues.
- Finasteride inhibits melanogenesis through regulation of the adenylate cyclase in melanocytes and me…
- The intriguing role of fibroblasts and in the chemopreventive and therapeutic effect of finasteride…
- Prostate zonal impact of 5α-reductase inhibitors on multiparametric MRI characteristics and detectio…
- SRD5A2 and emerging therapies in androgen-driven disorders.
- Temperature-dependent phase transition microemulsions for enhanced transdermal delivery of finasteri…
- Comment on Current Investigations into the Postfinasteride Syndrome.
- Food Administration and Not Genetic Variants Causes Pharmacokinetic Variability of Tadalafil and Fin…
- Short-term Effect of Tamsulosin and Finasteride Monotherapy and their Combination on Nigerian Men wi…
같은 제1저자의 인용 많은 논문 (5)
- The effect of finasteride in men with benign prostatic hyperplasia. 1992.
- Effects of finasteride (MK-906), a 5 alpha-reductase inhibitor, on circulating androgens in male volunteers.
- Finasteride: a clinical review.
- Evaluation of men on finasteride.
- The potential application of finasteride for chemoprevention of prostate cancer.
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- 피나스테리드가 전립선암 발생에 미치는 영향.
- COVID-19의 50가지 이상의 장기 후유증: 체계적 문헌고찰 및 메타분석.
- 양성 전립선 비대증의 임상적 진행에 대한 doxazosin, finasteride 및 병용 요법의 장기 효과.
- 양성 전립선 비대증 남성에서 급성 요폐의 위험과 수술적 치료 필요성에 대한 finasteride의 효과. Finasteride Long-Term Efficacy and Safety Study Group.
- 양성 전립선 비대증 남성에서 finasteride의 효과.
- 원형 탈모에 대한 전장유전체 연관성 연구는 선천면역과 적응면역 모두의 관여를 시사한다.